
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has demonstrated significant operating margin expansion, which is projected to exceed 16%, up from an earlier estimate of 13%. The company is anticipated to achieve impressive year-over-year growth in organ transplant volumes, with estimates indicating a 35.2% increase and sales growth of approximately 40.5% in Q4 2025, surpassing consensus estimates. Additionally, positive trends such as higher adoption rates of the Organ Care System and robust international growth rates are expected to further enhance the company’s financial outlook.
Bears say
TransMedics Group Inc. has faced challenges in Q3, as evidenced by sequential declines in aviation metrics, specifically daily flights and flight hours, which resemble early-year levels. Despite reporting product revenue growth of 33.1% year-over-year, it fell short of consensus estimates by approximately $1 million, and with a gross margin of 58.8% missing expectations, doubts surrounding effective salesforce scaling and market penetration have arisen. Additionally, concerns about potential regulatory risks, competition, and reimbursement changes could hinder the company’s future growth and overall market performance.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares